07:22 AM EDT, 08/08/2024 (MT Newswires) -- Nuvalent ( NUVL ) reported a Q2 net loss Thursday of $0.88 per diluted share, widening from a loss of $0.51 a year earlier.

Analysts polled by Capital IQ expected a loss of $0.76.

The clinical-stage biopharmaceutical company did not report any revenue for the quarter ended June 30.

Nuvalent ( NUVL ) said it had $658 million in cash, cash equivalents, and marketable securities as of June 30, and expects this could fund operations into 2027.